血脂管理与ASCVD的回顾与展望

彭道泉; 杨阳

doi:10.13201/j.issn.1001-1439.2020.09.001

血脂管理与ASCVD的回顾与展望

彭道泉^,,
杨阳

- 中南大学湘雅二医院心内科(长沙, 410011)

详细信息

通讯作者: 彭道泉,E-mail:pengdq@csu.edu.cn

中图分类号: R541.4

收稿日期: 2020-08-07

Retrospect and prospect of blood lipid management and ASCVD

PENG Daoquan^,,
YANG Yang

- Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, 410011, China

More Information

Corresponding author: PENG Daoquan, E-mail: pengdq@csu.edu.cn

Received Date: 07 August 2020

摘要

摘要: 更新的血脂指南中,一级预防危险分层引入增强的危险因素,二级预防中动脉粥样硬化性心血管疾病(ASCVD)风险再分层,低密度脂蛋白胆固醇(LDL-C)目标值进一步降低。联合降脂已成为趋势,用药种类、给药方式及治疗靶点均有全新呈现。
- 动脉粥样硬化性心血管疾病 /
- 低密度脂蛋白胆固醇 /
- 脂蛋白(a) /
- 前蛋白转化酶枯草溶菌素9抑制剂 /
- 血管生成素样因子3 /
- 鱼油
Abstract: In the updated blood lipid guidelines, the risk stratification of primary prevention introduces enhanced risk factors, the risk of atherosclerotic cardiovascular disease(ASCVD) in secondary prevention is further stratified, and the target value of low-density lipoprotein cholesterol(LDL-C) decreases further. Combined lipid-lowering has become a trend. The types of medications, methods of administration and therapeutic targets have been newly presented.
- atherosclerotic cardiovascular disease /
- low-density lipoprotein cholesterol /
- lipoprotein(a) /
- PCSK9 inhibitor /
- angiopoietin-like factor 3 /
- fish oil

HTML全文

参考文献(14)

[1]	Grundy SM,Stone NJ,Bailey AL,et al.2018 AHA/ ACC/ AACVPR/ AAPA/ ABC/ ACPM/ ADA/ AGS/ APhA/ ASPC/ NLA/ PCNA Guideline on the Management of Blood Cholesterol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].J Am Coll Cardiol,2019,73(24):e285-e350.
[2]	Mach F,Baigent C,Catapano AL,et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J].Eur Heart J,2020,41(1):111-188.
[3]	中国胆固醇教育计划(CCEP)工作委员会.中国胆固醇教育计划调脂治疗降低心血管事件专家建议(2019)[J].中华内科杂志,2020,59(1):18-22.
[4]	中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华心血管病杂志编辑委员会.超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J].中华心血管病杂志,2020,48(4):280-286.
[5]	Ray KK,Wright RS,Kallend D,et al.Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J].N Engl J Med,2020,382(16):1507-1519.
[6]	Raal FJ,Kallend D,Ray KK,et al.Inclisiran for the treatment of heterozygous familial hypercholesterolemia[J].N Engl J Med,2020,382(16):1520-1530.
[7]	Dewey FE,Gusarova V,Dunbar RL,et al.Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease[J].N Engl J Med,2017,377(3):211-221.
[8]	Banerjee P,Chan KC,Tarabocchia M,et al.Functional analysis of LDLR (Low-Density Lipoprotein Receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity[J].Arterioscler Thromb Vasc Biol,2019,39(11):2248-2260.
[9]	Tsimikas S,Viney NJ,Hughes SG,et al.Antisense therapy targeting apolipoprotein(a):a randomised,double-blind,placebo-controlled phase 1 study[J].Lancet,2015,386(10002):1472-1483.
[10]	Viney NJ,van Capelleveen JC,Geary RS,et al.Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a):two randomised,double-blind,placebo-controlled,dose-ranging trials[J].Lancet,2016,388(10057):2239-2253.
[11]	Tsimikas S,Karwatowska-Prokopczuk E,GouniBerthold I,et al.Lipoprotein(a)reduction in persons with cardiovascular disease[J].N Engl J Med,2020,382(3):244-255.
[12]	ASCEND Study Collaborative Group.Effects of n-3fatty acid supplements in diabetes mellitus[J].N Engl J Med,2018,379(16):1540-1550.
[13]	Bhatt DL,Steg PG,Miller M,et al.Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J].N Engl J Med,2019,380(1):11-22.
[14]	Marston NA,Giugliano RP,Im K,et al.Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes:a systematic review and meta-regression analysis of randomized controlled trials[J].Circulation,2019,140(16):1308-1317.